title: Predicting prognosis of rectal cancer patients with total mesorectal excision using molecular markers.
abstract: OBJECTIVE
  To explore the prognostic variables in rectal cancer patients undergoing curative total mesorectal excision and the effect of postoperative chemotherapy in advanced rectal cancer.
  
  
  METHODS
  A total of 259 consecutive rectal cancer patients treated with curative total mesorectal excision between 1999 and 2004 were collected. p53, p21, PCNA, and CD44v6 were examined using immunohistochemistry (IHC). The correlation between clinicopathological or molecular variables and clinical outcomes, including local recurrence, metastasis, disease-free survival and overall survival, was analyzed.
  
  
  RESULTS
  The median follow-up was 44 mo. Five-year survival rates and 5-year disease free survival rates were 75.43% and 70.32%, respectively. Multi-analysis revealed TNM staging, preoperative CEA, and CD44v6 level were independent risk factors predicting overall survival or disease free survival. The hazard ratio of peroperative CEA was 2.65 (95% CI 1.4-5) and 3.10 (95% CI 1.37-6.54) for disease free survival and overall survival, respectively. The hazard ratio of CD44v6 was 1.93 (95% CI 1.04-3.61) and 2.21 (95% CI 1.01-4.88) for disease free survival and overall survival, respectively. TNM staging was the only risk factor predicting local recurrence. Postoperative chemotherapy without radiotherapy did not improve patients' outcome.
  
  
  CONCLUSIONS
  TNM staging, preoperative CEA and CD44v6 were independent prognostic factors for rectal cancer patients with total mesorectal excision. Postoperative chemotherapy may be only used together with radiotherapy for rectal cancer patients.
authors.affiliation: Department of Oncology, Shanghai Medical College, Fudan University, 270 Dong'an Road, Shanghai 200032, China.
authors.forename: Jun-Jie
authors.initials: JJ
authors.lastname: Peng
authors.forename: San-Jun
authors.initials: SJ
authors.lastname: Cai
authors.forename: Hong-Feng
authors.initials: HF
authors.lastname: Lu
authors.forename: Guo-Xiang
authors.initials: GX
authors.lastname: Cai
authors.forename: Peng
authors.initials: P
authors.lastname: Lian
authors.forename: Zu-Qing
authors.initials: ZQ
authors.lastname: Guan
authors.forename: Ming-He
authors.initials: MH
authors.lastname: Wang
authors.forename: Ye
authors.initials: Y
authors.lastname: Xu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002272:Carcinoembryonic Antigen / Q000235:genetics / Q000378:metabolism*; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000235:genetics / Q000378:metabolism; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006023:Glycoproteins / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D018960:Hyaluronan Receptors / Q000235:genetics / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging / Q000379:methods*; D011237:Predictive Value of Tests; D011379:Prognosis; D018809:Proliferating Cell Nuclear Antigen / Q000235:genetics / Q000378:metabolism; D012004:Rectal Neoplasms / Q000378:metabolism* / Q000473:pathology* / Q000601:surgery; D012007:Rectum / Q000601:surgery; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism
chemical_list: C112697:CD44v6 antigen; C493956:CDKN1A protein, human; D002272:Carcinoembryonic Antigen; D050759:Cyclin-Dependent Kinase Inhibitor p21; D006023:Glycoproteins; D018960:Hyaluronan Receptors; D018809:Proliferating Cell Nuclear Antigen; D016159:Tumor Suppressor Protein p53